+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18



Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18



American Heart Journal 148(1): 173-180



Few data are available about development of congestive heart failure (CHF) in patients with unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI). We developed and validated a risk score to predict which patients will develop CHF. A subset of 4681 patients from the Orbofiban in Patients With Unstable Coronary Syndromes-Thrombolysis in Myocardial Infarction (OPUS-TIMI 16) trial with UA/NSTEMI and without a history of CHF were included in this analysis and stratified according to the development of CHF at 10 months. A risk score was created from significant variables and validated in the Treat Angina With Aggrastat and Determine Cost of Therapy With an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction (TACTICS-TIMI 18) trial. B-type natriuretic peptide (BNP) was then added to the initial multivariate analysis and validated in the TACTICS-TIMI 18 trial. The incidence of CHF at 30 days was 4.9%, and at 10 months it was 5.6%. Significant variables on multivariate analysis included age >65 years, heart rate >100 beats/min, history of diabetes mellitus, lateral electrocardiographic changes, and history of angiographically confirmed coronary artery disease. The risk of CHF increased 10-fold across the number of risk factors (P <.001). When validated in the TACTICS-TIMI 18 trial, the risk score was significantly associated with CHF at 6 months (P =.01). The median BNP value doubled across the number of risk factors (P <.001 for trend). The addition of BNP to the risk score improved its discriminatory capacity. In patients with UA/NSTEMI, a simple clinical risk score can aid in assessing the risk of developing CHF. BNP adds to the predictive capacity of this risk score. This score may assist in identifying patients who warrant more careful monitoring and therapy for CHF prevention inhospital and during follow-up.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012733969

Download citation: RISBibTeXText

PMID: 15215808

DOI: 10.1016/j.ahj.2003.12.018


Related references

A validated risk score predicts the development of congestive heart failure and correlates with B-type natriuretic peptide after presentation with unstable angina or non-ST elevation myocardial infarction Results from OPUS-TIMI 16 and TIMI 11B. Circulation 106(19 Suppl.): II 402, 2002

Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. American Journal of Cardiology 90(3): 303-305, 2002

Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial. American Heart Journal 157(4): 673-9.E1, 2009

Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Circulation 109(7): 874-880, 2004

TIMI Risk Score to predict 6-month mortality, recurrent cardiac events, and relative benefit of invasive vs conservative strategy in patients with unstable angina Results from TACTICS-TIMI 18. Journal of the American College of Cardiology 37(2 Suppl. A): 335A-336A, 2001

A prospective evaluation of the TIMI risk score for unstable angina and non-ST-elevation myocardial infarction. Circulation 104(17 Suppl.): II 728, 2001

TIMI risk score underestimates prognosis in unstable angina/non-ST segment elevation myocardial infarction. Acute Cardiac Care 10(1): 26-29, 2008

Validation of the Thrombolysis In Myocardial Infarction risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. American Journal of Cardiology 90(3): 303-305, 2002

Can risk stratification using TIMI score of unstable angina/non-ST elevation myocardial infarction predict short-term outcome after percutaneous coronary intervention?. Journal of the American College of Cardiology 39(5 Suppl. A): 39A, 2002

Gender differences in cardiac biomarkers in patients with unstable angina and non-ST elevation myocardial infarction in TACTICS-TIMI 18. Journal of the American College of Cardiology 41(6 Suppl. A): 341A, 2003

Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation 109(5): 580-586, 2004

Sequential risk stratification using the TIMI Risk Score and the TIMI Flow Grade among patients treated with fibrinolytic therapy for acute ST segment elevation myocardial infarction. Circulation 108(17 Suppl.): IV-679, 2003

Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. American Journal of Cardiology 94(9): 1113-1117, 2004

The TIMI risk score for ST elevation myocardial infarction A convenient bedside clinical score for risk assessment at presentation. Circulation 102(18 Suppl.): II 590, 2000

GRACE Score among Six Risk Scoring Systems (CADILLAC, PAMI, TIMI, Dynamic TIMI, Zwolle) Demonstrated the Best Predictive Value for Prediction of Long-Term Mortality in Patients with ST-Elevation Myocardial Infarction. Plos one 10(4): E0123215, 2015